Least Developed Countries (LDCs) vs Oman: Percentage of bloodstream infection due to Escherichia coli resistant
Least Developed Countries (LDCs)
73.5%
in 2022
Oman
78.2%
in 2022
Least Developed Countries (LDCs) rank
4th
Oman rank
3rd
Percentage of bloodstream infection due to Escherichia coli resistant over time
- Least Developed Countries (LDCs)
- Oman
How they compare
Oman currently reports 78.2% against 73.5% in Least Developed Countries (LDCs), a difference of 4.7%.
That makes Oman's figure about 1.1 times Least Developed Countries (LDCs)'s.
The two have swapped places 4 times across 6 shared years of data; in 2017 it was Oman ahead.
Least Developed Countries (LDCs) ranks 4th and Oman ranks 3rd of 16 groups.
Oman has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Least Developed Countries (LDCs) | Oman | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 51.7% | 52.1% | 0.4% | Oman |
| 2020s | 72.7% | 73.7% | 0.9% | Oman |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher percentage of bloodstream infection due to escherichia coli resistant, Least Developed Countries (LDCs) or Oman?
- Oman, at 78.2% against 73.5% in Least Developed Countries (LDCs) as of 2022.
- What is the difference in percentage of bloodstream infection due to escherichia coli resistant between Least Developed Countries (LDCs) and Oman?
- 4.7%, with Oman ahead.
- How many years of comparable data are there for Least Developed Countries (LDCs) and Oman?
- 6 years are reported by both, from 2017 to 2022.
- How do Least Developed Countries (LDCs) and Oman rank globally for percentage of bloodstream infection due to escherichia coli resistant?
- Least Developed Countries (LDCs) ranks 4th and Oman ranks 3rd of 16 groups.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Percentage of bloodstream infection due to Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.